Search results
Showing 841 to 855 of 1423 results for primary care
medicines and improve patient outcomes from medicines, compared with usual care, in the UK setting? Any explanatory notes(if applicable)...
FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)
This advice has been updated and replaced by NICE medtech innovation briefing 224.
therapy, computer-aided biofeedback therapy and attention control in primary care. Participants should be adults with a positive...
College of Surgeons, is that every emergency department should include a primary care out-of-hours facility. This approach deserves...
This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Cytosponge for detecting abnormal cells in the oesophagus (MIB240)
NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (HTG122)
Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.
View recommendations for HTG122Show all sections
Sections for HTG122
We have moved Diagnostics guidance 56 to become HealthTech guidance 690. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.